The Latest

  • Weight loss GLP-1
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

    At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

  • 3d DNA chain link
    Image attribution tooltip

    Shutterstock / DaveMF

    Image attribution tooltip
    Sponsored by Marken

    Precision under pressure: Logistic solutions for nuclear medicine scalability

    Racing the clock: How precision logistics deliver life-saving nuclear medicine.

  • An infant's left ear is in the foreground of this image, which is otherwise blurred.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    So far in 2026 a dozen drugmakers have gone public and raised a median of about $300 million each, a significant spike from previous years.

    Updated June 10, 2026
  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Ethyreal starts up with $101M and takes aim at a pair of immune diseases

    The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK boosts cancer pipeline with $11B Nuvalent buyout

    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    GSK’s $10.6 billion acquisition of Nuvalent is its third company buyout since late January and the biopharmaceutical sector’s second-largest deal this year.

    Updated June 9, 2026
  • A person stands next to a table where another person sits.
    Image attribution tooltip
    Courtesy of Treeline Biosciences
    Image attribution tooltip
    Emerging biotech

    Stealthy startup Treeline plans a reverse merger

    Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

  • Johnson & Johnson's new logo is seen on an office lobby wall.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip
    Emerging biotech

    J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B

    The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

    Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    AstraZeneca, Pfizer and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025 — surpassing all of their pharmaceutical peers over that timeframe.

    Updated June 1, 2026
  • lung target
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

    While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

  • Illustration of a blood clot blocking red blood cells within an artery or a vein.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    City banks nearly $100M for next-gen RNAi drugs

    Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

  • Pancreatic cancer cells are stained pink in this micrograph image.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tango data add to growing momentum for pancreatic cancer drugs

    A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    RA Capital Management is investing $30 million in Secretome Therapeutics, a company developing a new kind of cell therapy for the heart muscle weakness associated with Duchenne muscular dystrophy.

    Updated May 28, 2026
  • An illustration of red blood cells
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Incyte to buy blood disorder drug in possibly $2B deal

    Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche stakes $700M on Nurix’s protein-degrading drug

    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

  • capitol china flag
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    House bill aims to crack down on China biotech deals

    A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.

  • Image of a brain in purple outline with red details.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Study data convince Lundbeck to push new migraine drug forward

    A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.

  • The outside of the U.S. Supreme Court with blue sky and clouds in the background.
    Image attribution tooltip
    Fintan Trimble via Getty Images
    Image attribution tooltip

    Generic drugmakers gain key victory in ‘skinny label’ patent case

    The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

    At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Otsuka showcases kidney drug data; Pfizer cuts an AI deal

    Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.

  • An Alnylam logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Alnylam, Inceptive ink AI deal potentially worth $2B

    The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

    Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.

  • A Lilly sign is seen on the side of a building viewed through pine trees
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Lilly, Ascidian link up in RNA exon editing pact

    Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.